Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19

JR Arribas, S Bhagani, SM Lobo, I Khaertynova… - NEJM …, 2022 - evidence.nejm.org
Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …
被引用次数：118 相关文章
[PDF] archive.org

[PDF][PDF] Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19

JR Arribas, S Bhagani, SM Lobo, I Khaertynova… - scholar.archive.org
BACKGROUND Molnupiravir is an oral prodrug of bD-N4-hydroxycytidine, active against
SARS-CoV-2 in vitro and in animal models. We report data from the phase 2 component of …

Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19

JR Arribas, S Bhagani, SM Lobo… - NEJM …, 2022 - pubmed.ncbi.nlm.nih.gov
Molnupiravir or Placebo in Patients with Covid-19 Molnupiravir is an oral agent, a metabolite
of which has activity against SARS-CoV-2. In a controlled phase 2 trial in adults hospitalized …

Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.

JR Arribas, S Bhagani, SM Lobo, I Khaertynova… - NEJM …, 2021 - europepmc.org
Molnupiravir or Placebo in Patients with Covid-19 Molnupiravir is an oral agent, a metabolite
of which has activity against SARS-CoV-2. In a controlled phase 2 trial in adults hospitalized …

[引用][C] Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19

JR Arribas, S Bhagani, SM Lobo, I Khaertynova… - NEJM Evidence, 2022 - cir.nii.ac.jp
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19 | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学 …